Cancer researchers unable to access clinical trial data for top-selling drugs, study finds

Lack of transparency from pharmaceutical companies on anticancer medication has implications for health equity, Australian scientist says

• Get our free news app, morning email briefing or daily news podcast

Clinical trial data that saw some of the world's most widely used cancer drugs approved by the US drugs regulator remains secret, despite a pharmaceutical industry commitment to transparency made in 2014.

The authors of a study published in the journal JAMA Oncology on Friday said the lack of transparency should be concerning to Australia.

Sign up to receive an email with the top stories from Guardian Australia every morning